4D Path, a Newton, Massachusetts-based cancer treatment prediction company, announced completion of the first close of a strategic financing round and the appointment of two new board members.

Katherine Vega Stultz and Robert J. Hombach joined the company's board of directors. Stultz will serve as board chair, according to the company's statement.

The financing will support development of treatment predictive biomarkers for clinical use and partnerships with biopharmaceutical companies. The company did not disclose the amount raised.

Stultz currently serves as CEO and president of BrainXell Therapeutics Global Inc. She previously worked at Celgene, where she directed clinical project organization worldwide and oversaw more than 30 mid and late-stage clinical programs in hematology and oncology.

Hombach previously served as executive vice president, chief financial officer and chief operations officer of Baxalta (NYSE: BXLT), a biopharmaceutical company acquired by Shire plc in 2016. He has board experience with companies including BioMarin (NASDAQ: BMRN) and Seaport Therapeutics.

4D Path develops digital biomarkers designed to predict tumor response to therapy using what it describes as a physics-informed approach. The company states it has delivered results across breast, ovarian, colorectal and skin cancers.

"Their addition coupled with our strategic financing will serve as a catalyst to bring this promising treatment predictive technology one step closer to helping patients around the world beat cancer," said Jacopo Leonardi, CEO of 4D Path.

The company's platform, called Q-Plasia OncoReader, measures cell cycle deregulation and tumor immune microenvironment dynamics to predict patient response to therapy, according to the company.